MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
1616.19%
Quick Ratio
1616.19%
Cash Ratio
138.28%
Debt to Asset Ratio
5.83%
Unit: Thousand (K) dollars
Assets Breakdown
    • Cash and cash equivalents
    • Investment in angel pharmaceutic...
    • Other assets
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Total current liabilities
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
18,905
40,102
4,576
2,867
Marketable securities
196,323
196,612
52,174
62,822
Accounts receivable
6
43
37
32
Prepaid and other current assets
5,731
3,189
1,427
1,223
Total current assets
220,965
239,946
58,214
66,944
Property and equipment, net
830
282
220
221
Operating lease right-of-use asset
659
751
839
927
Investment in angel pharmaceuticals
15,107
10,496
10,991
11,530
Other assets
1,713
1,720
855
852
Total assets
239,274
253,195
71,119
80,474
Accounts payable
4,047
4,697
2,491
1,974
Operating lease liability
454
428
403
379
Accrued and other liabilities
9,171
6,985
6,486
5,721
Total current liabilities
13,672
12,110
9,380
8,074
Operating lease liability
274
406
534
632
Total liabilities
13,946
12,516
9,914
8,706
Common stock 0.0001 par value 290,000,000 shares authorized at june 30, 2026 and december 31, 2025 84,120,944 and 74,696,629 shares issued and outstanding at june 30, 2026 and december 31, 2025, respectively
8
8
7
7
Additional paid-in capital
670,557
667,782
474,387
472,793
Accumulated other comprehensive loss
-1,293
-1,126
-896
-1,060
Accumulated deficit
-443,944
-425,985
-412,293
-399,972
Total stockholders' equity
225,328
240,679
61,205
71,768
Total liabilities and stockholders' equity
239,274
253,195
71,119
80,474
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Marketable securities$196,323K (228.76%↑ Y/Y)Cash and cashequivalents$18,905K (28.68%↑ Y/Y)Prepaid and othercurrent assets$5,731K (345.30%↑ Y/Y)Accounts receivable$6K (-93.02%↓ Y/Y)Total current assets$220,965K (191.59%↑ Y/Y)Investment in angelpharmaceuticals$15,107K (28.09%↑ Y/Y)Other assets$1,713K (173.64%↑ Y/Y)Property and equipment,net$830K (233.33%↑ Y/Y)Operating leaseright-of-use asset$659K (-34.88%↓ Y/Y)Total assets$239,274K (167.46%↑ Y/Y)Total liabilities andstockholders' equity$239,274K (167.46%↑ Y/Y)Total stockholders'equity$225,328K (180.86%↑ Y/Y)Total liabilities$13,946K (51.05%↑ Y/Y)Accumulated deficit-$443,944K (-13.89%↓ Y/Y)Accumulated othercomprehensive loss-$1,293K (-12.63%↓ Y/Y)Additional paid-in capital$670,557K (42.31%↑ Y/Y)Total currentliabilities$13,672K (60.75%↑ Y/Y)Operating lease liability$274K (-62.36%↓ Y/Y)Common stock 0.0001 parvalue 290,000,000...$8K (14.29%↑ Y/Y)Accrued and otherliabilities$9,171K (82.94%↑ Y/Y)Accounts payable$4,047K (29.01%↑ Y/Y)Operating lease liability$454K (27.89%↑ Y/Y)

Corvus Pharmaceuticals, Inc. (CRVS)

Corvus Pharmaceuticals, Inc. (CRVS)